文献速递心脑血管急症

澳大利亚人群队列中戒烟药物心血管安全性比较

Comparison of Cardiovascular Safety for Smoking Cessation Pharmacotherapies in a Population-Based Cohort in Australia.
PubMed 文献 · JAMA Netw Open · 2021-11-01
一句话结论基于澳大利亚新南威尔士州人群队列,伐尼克兰与尼古丁贴片的心血管主要不良事件风险无显著差异(HR 0.87,95%CI 0.72-1.07)。

该回顾性、基于人群的队列研究利用澳大利亚新南威尔士州的药品发放、住院和死亡链接数据,比较伐尼克兰、尼古丁贴片和安非他酮起始者发生主要不良心血管事件(MACE)的风险。结果显示,伐尼克兰与尼古丁贴片起始者MACE风险无显著差异(HR 0.87,95%CI 0.72-1.07),急性冠脉综合征和卒中风险亦无显著差异,但伐尼克兰组心血管死亡风险降低(HR 0.49,95%CI 0.30-0.79)。涉及安非他酮的比较因置信区间宽而不确定。作者认为伐尼克兰与尼古丁贴片MACE风险相似,可替代使用而不增加主要心血管事件风险,但需进一步大规模研究比较伐尼克兰和尼古丁贴片与安非他酮的心血管安全性。

要点

  • 伐尼克兰与尼古丁贴片起始者MACE风险无显著差异(HR 0.87,95%CI 0.72-1.07)。
  • 伐尼克兰组心血管死亡风险低于尼古丁贴片组(HR 0.49,95%CI 0.30-0.79)。
  • 伐尼克兰与尼古丁贴片组急性冠脉综合征(HR 0.96,95%CI 0.76-1.21)和卒中(HR 0.72,95%CI 0.45-1.14)风险无显著差异。
  • 涉及安非他酮的比较因置信区间宽而不确定(MACE:伐尼克兰 vs 安非他酮 HR 0.87,95%CI 0.53-1.41;尼古丁贴片 vs 安非他酮 HR 0.79,95%CI 0.39-1.62)。
  • 作者认为伐尼克兰可替代尼古丁贴片而不增加主要心血管事件风险,但需进一步大规模研究比较二者与安非他酮的心血管安全性。

适用人群与场景

  • 2008年至2015年或2011年至2015年(取决于所比较药物的可及性)在澳大利亚新南威尔士州接受处方戒烟药物治疗的成年人。
  • 纳入比较的起始者:伐尼克兰122 932例 vs 尼古丁贴片92 148例;伐尼克兰342 064例 vs 安非他酮10 457例;尼古丁贴片102 817例 vs 安非他酮6056例。
  • 纳入人群平均(SD)年龄范围41.9(14.2)至49.8(14.9)岁,女性比例范围42.8%(52 702/123 128)至52.2%(53 693/102 913)。

研究设计与关键结果

  • 研究类型:回顾性、基于人群的队列研究,使用链接的药品发放、住院和死亡数据,在澳大利亚新南威尔士州开展;采用逆概率治疗加权与高维倾向评分控制混杂,Cox比例风险回归模型(稳健方差)估计HR和95%CI;数据分析时间为2019年1月24日至2021年9月1日。
  • 主要终点MACE定义为急性冠脉综合征、卒中和心血管死亡的复合终点;次要终点为MACE各组分。
  • 伐尼克兰 vs 尼古丁贴片:MACE风险无显著差异(HR 0.87,95%CI 0.72-1.07);急性冠脉综合征无显著差异(HR 0.96,95%CI 0.76-1.21);卒中无显著差异(HR 0.72,95%CI 0.45-1.14);心血管死亡风险降低(HR 0.49,95%CI 0.30-0.79)。
  • 伐尼克兰 vs 安非他酮:MACE风险HR 0.87(95%CI 0.53-1.41),因置信区间宽结果不确定。
  • 尼古丁贴片 vs 安非他酮:MACE风险HR 0.79(95%CI 0.39-1.62),因置信区间宽结果不确定。

证据类型、等级与局限

  • 证据类型:回顾性、基于人群的队列研究。
  • 局限:涉及安非他酮的比较因置信区间宽而不确定;作者指出需进一步大规模研究比较伐尼克兰和尼古丁贴片与安非他酮的心血管安全性。

对床旁实践的改变

  • 作者认为,伐尼克兰与尼古丁贴片MACE风险相似,伐尼克兰(最有效的戒烟药物)可替代尼古丁贴片处方而不增加主要心血管事件风险。
  • 作者指出,需进一步大规模研究比较伐尼克兰和尼古丁贴片与安非他酮的心血管安全性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Although concerns exist regarding a potential increased risk of cardiovascular events for smoking cessation pharmacotherapies, there is general consensus that any increased risk associated with their use would be outweighed by the benefits of smoking cessation; thus, clinical guidelines recommend that such pharmacotherapies be offered to everyone who wants to quit smoking. In the interest of minimizing risk to patients, prescribers need evidence indicating how these pharmacotherapies compare with one another in terms of cardiovascular safety.

OBJECTIVE: To compare the risk of major adverse cardiovascular events (MACE) among individuals initiating varenicline, nicotine replacement therapy (NRT) patches, or bupropion.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective, population-based cohort study using linked pharmaceutical dispensing, hospital admissions, and death data was conducted in New South Wales, Australia. Participants included adults who were dispensed a prescription smoking cessation pharmacotherapy between 2008 and 2015 or between 2011 and 2015, depending on the availability of the pharmacotherapies being compared. Pairwise comparisons were conducted for risk of MACE among 122 932 varenicline vs 92 148 NRT initiators; 342 064 varenicline vs 10 457 bupropion initiators; and 102 817 NRT vs 6056 bupropion initiators.

EXPOSURE: First course of the smoking cessation pharmacotherapy of interest.

MAIN OUTCOMES AND MEASURES: The primary outcome was MACE, defined as a composite of acute coronary syndrome, stroke, and cardiovascular death. Secondary outcomes were the individual components of MACE. Inverse probability of treatment weighting with high-dimensional propensity scores was used to account for potential confounding. Cox proportional hazards regression models with robust variance were used to estimate hazard ratios (HRs) and 95% CIs. Data were analyzed January 24, 2019, to September 1, 2021.

RESULTS: The mean (SD) age of included individuals ranged from 41.9 (14.2) to 49.8 (14.9) years, and the proportion of women ranged from 42.8% (52 702 of 123 128) to 52.2% (53 693 of 102 913). The comparison of 122 932 varenicline initiators and 92 148 NRT patch initiators showed no difference in the risk of MACE (HR, 0.87; 95% CI, 0.72-1.07) nor in the risk of the secondary outcomes of acute coronary syndrome (HR, 0.96; 95% CI, 0.76-1.21) and stroke (HR, 0.72; 95% CI, 0.45-1.14). However, decreased risk of cardiovascular death was found among varenicline initiators (HR, 0.49; 95% CI, 0.30-0.79). The results of comparisons involving bupropion were inconclusive owing to wide confidence intervals (eg, risk of MACE: 342 064 varenicline vs 10 457 bupropion initiators, HR, 0.87 [95% CI, 0.53-1.41]; 102 817 NRT patch vs 6056 bupropion initiators, HR, 0.79 [95% CI, 0.39-1.62]).

CONCLUSIONS AND RELEVANCE: The finding of this cohort study that varenicline and NRT patch use have similar risk of MACE suggests that varenicline, the most efficacious smoking cessation pharmacotherapy, may be prescribed instead of NRT patches without increasing risk of major cardiovascular events. Further large-scale studies of the cardiovascular safety of varenicline and NRT relative to bupropion are needed.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Havard A, Choi SKY, Pearson SA, et al. Comparison of Cardiovascular Safety for Smoking Cessation Pharmacotherapies in a Population-Based Cohort in Australia. JAMA Netw Open. 2021. PMID: 34842922. doi:10.1001/jamanetworkopen.2021.36372

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。